Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) commended the American College of Rheumatology (ACR) for its newly released 2024 evidence-based guidelines on the screening, treatment, and management of lupus nephritis (LN). The…
RheaVita, a leader in controlled, continuous freeze-drying technology for biopharmaceuticals, has entered into a strategic partnership with IMA Life, a global leader in advanced aseptic pharmaceutical production solutions and one…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leader in RNA interference (RNAi) therapeutics, today announced positive new results from its ongoing Phase 1 clinical trial of nucresiran (formerly ALN-TTRsc04), an investigational…
Alpha Cognition Inc. (NASDAQ: ACOG) (CSE: ACOG), a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, has released its financial results for the second quarter and six months ending…
Cardinal Health recently celebrated the grand opening of its new Scientific Services Chemistry Center in Mansfield, Massachusetts. This state-of-the-art, FDA-regulated laboratory spans nearly 26,000 square feet and is designed to…
Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe ischemic diseases, today announced that the first patient has been dosed in its investigator-sponsored…
Geron Corporation (Nasdaq: GERN), a biopharmaceutical leader focused on transforming the treatment of blood cancers, announced today the appointment of Joseph Eid, M.D., as Executive Vice President of Research and…
Cyrus Biotechnology, Inc., a Seattle-based biotech company leveraging a novel hybrid AI/screening platform for biologics discovery, will showcase its expertise in protein engineering and risk mitigation for therapeutics at the…
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing innovative logic-gated cell therapies to selectively target tumor cells while sparing normal cells, today presented updates on its Tmod™…
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced that on November 8, 2024, its Compensation Committee granted inducement awards to seven new employees under the company’s 2020 Inducement Plan. These awards consist…
Palleon Pharmaceuticals, a clinical-stage company leading innovation in glyco-immunology for autoimmune diseases and cancer, today announced results from the Phase 1/2 GLIMMER-01 trial of E-602. This first-in-class human sialidase enzyme…